NCT00769964

Brief Summary

This is a first-in-human study of VA111913 TS, a new chemical entity being developed for the treatment of dysmenorrhea. This study is designed to investigate determine the safety, tolerability and pharmacokinetics of VA111913 TS after single and multiple doses in healthy non-pregnant female volunteers of child bearing age.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Sep 2008

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 8, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 9, 2008

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2009

Completed
Last Updated

June 25, 2009

Status Verified

June 1, 2009

Enrollment Period

6 months

First QC Date

October 8, 2008

Last Update Submit

June 24, 2009

Conditions

Keywords

Healthy (Dysmenorrhea)

Interventions

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy females 18 to 45 years of age.
  • Subjects must have a negative pregnancy test at screening and admission. Using acceptable form of contraceptive during and after study.

You may not qualify if:

  • Administration of any IMP within 12 weeks before entry to the study or any prescribed medicine within 14days of the study.
  • Any clinically important medical disease, condition or abnormal laboratory test results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Charles River Clinical Services

Edinburgh, EH33 2NE, United Kingdom

Location

MeSH Terms

Conditions

Dysmenorrhea

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPelvic PainPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
phase 1
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 8, 2008

First Posted

October 9, 2008

Study Start

September 1, 2008

Primary Completion

March 1, 2009

Study Completion

March 1, 2009

Last Updated

June 25, 2009

Record last verified: 2009-06

Locations